Major depressive disorder: An organic disorder!
Yrondi A, Sporer M, Schmitt L, Arbus C.
Presse Med. 2018 Feb;47(2):113-115. doi: 10.1016/j.lpm.2017.12.005.
Vortioxetine's cardiovascular profile as a relevant feature for the management of major depressive disorder in comorbidity with organic diseases.
Dell'osso B, Blasi G, Serafini G, Serrati C, Bianchetti A, Porto I, Forleo GB, Pugliese A, Mastrostefano A, Nicoletti F.
Expert Rev Neurother. 2026 Feb;26(2):175-184. doi: 10.1080/14737175.2025.2602193. Epub 2025 Dec 29.
Treatment-resistant depression.
Souery D, Papakostas GI, Trivedi MH.
J Clin Psychiatry. 2006;67 Suppl 6:16-22.
Pseudo-melancholia.
Parker G.
Australas Psychiatry. 2020 Jun;28(3):339-341. doi: 10.1177/1039856220908167. Epub 2020 Mar 11.
Bright light therapy.
Prasko J.
Neuro Endocrinol Lett. 2008 Nov;29 Suppl 1:33-64.
Gut-brain axis volatile organic compounds derived from breath distinguish between schizophrenia and major depressive disorder.
Henning D, Lüno M, Jiang C, Meyer-Lotz G, Hoeschen C, Frodl T.
J Psychiatry Neurosci. 2023 Apr 12;48(2):E117-E125. doi: 10.1503/jpn.220139. Print 2023 Mar-Apr.
[Psychosomatic and organic etiology of depressive disorder].
Omori T.
Seishin Shinkeigaku Zasshi. 2007;109(9):844-5.
Overview: pseudodementia.
McAllister TW.
Am J Psychiatry. 1983 May;140(5):528-33. doi: 10.1176/ajp.140.5.528.
Psychogenic gait disorders.
Sudarsky L.
Semin Neurol. 2006 Jul;26(3):351-6. doi: 10.1055/s-2006-945523.
[The role of premorbid personality in the genesis of psychopathological symptomatology in patients with organic anxiety-depressive disorder, schizophrenia and endogenous depression].
Kalinin VV, Syrtsev MA, Zemlyanaya AA, Fedorenko EA, Sokolova LV.
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7):94-99. doi: 10.17116/jnevro202212207194.
